SCHEMBL23059883

SCHEMBL23059883

Cc1ccc2c(c1)Nc1cc(C(F)(F)F)ccc1S2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOX1 Q9Y5S8 7/20 0.69
▸ CYBB P04839 1/20 0.69
▸ NOX3 Q9HBY0 1/20 0.69
▸ NOX4 Q9NPH5 1/20 0.69
▸ MAPT P10636 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ KIF11 P52732 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ JUN P05412 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ PTPN5 P54829 1/20 0.41
▸ ATP4A P20648 1/20 0.37
▸ ATP4B P51164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL225814 0.84 NOX1 (0.47) NOX1CYBBNOX3NOX4MAPT
SCHEMBL560225 0.81 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
Phenothiazine SCHEMBL6532335 0.81 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
SCHEMBL29475150 0.81 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
Benzene SCHEMBL29242186 0.80 NOX1 (0.97) NOX1CYBBNOX3NOX4MAPT
SCHEMBL10193005 0.80 MAPT (0.65) NOX1CYBBNOX3NOX4MAPT
SCHEMBL6998043 0.78 NOX1 (0.56) NOX1CYBBNOX3NOX4MAPT
SCHEMBL11375009 0.78 NOX1 (0.69) NOX1CYBBNOX3NOX4MAPT
SCHEMBL2756476 0.77 NOX1 (0.53) NOX1CYBBNOX3NOX4MAPT
SCHEMBL20842835 0.76 NOX1 (0.68) NOX1CYBBNOX3NOX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-25 — — US disclosed
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-25 — — US disclosed
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-25 — — US disclosed
US-11542290-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2023-01-03 — — US disclosed
WO-2022104070-A2 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-05-19 — — WO disclosed
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2021-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 NOX1 3644/4885CYBB 2306/4885NOX3 3865/4885
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ACE2, BACE2, PSEN2 NOX1 2388/4885CYBB 1614/4885NOX3 2630/4885
US-11542290-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 NOX1 3644/4885CYBB 2306/4885NOX3 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback